NSC 405020

NSC 405020 is a specific MMP14 inhibitor. NSC 405020 can directly interact with the hemopexin domain of MMP14. NSC 405020 reduces the expression of full length and active cleaved Notch3 (NICD3) . NSC 405020 can be used to research vestibular schwannoma, hemostasis and thrombosis[1][2][3].

Product Specifications

CAS Number

[7497-07-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

MMP

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/NSC-405020.html

Purity

99.63

Solubility

DMSO : ≥ 260 mg/mL

Smiles

O=C(NC(C)CCC)C1=CC=C(Cl)C(Cl)=C1

Molecular Formula

C12H15Cl2NO

Molecular Weight

260.16

Precautions

H302, H315, H319, H335

References & Citations

[1]Ren Y, et al. MMP-14 (MT1-MMP) Is a Biomarker of Surgical Outcome and a Potential Mediator of Hearing Loss in Patients With Vestibular Schwannomas. Front Cell Neurosci. 2020 Jul 28;14:191.|[2]Pekkonen P, et al. Lymphatic endothelium stimulates melanoma metastasis and invasion via MMP14-dependent Notch3 and β1-integrin activation. Elife. 2018 May 1;7:e32490.|[3]Mastenbroek TG, et al. Platelet-Associated Matrix Metalloproteinases Regulate Thrombus Formation and Exert Local Collagenolytic Activity. Arterioscler Thromb Vasc Biol. 2015 Dec;35 (12) :2554-61.